IMPACTO AMBIENTAL

1. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF. Cost analysis of pancreatic cancer treatment. Cancer 2000; 89: 1917-24.

2. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone or interferon β-1b in the treatment of patients with secondary-progressive or progressive-relapsing multiple sclerosis. Clinical Therapeutics 2003; 25: 611-634.

3. Hunt J, Siemienczuk J, Touchette DR, Payne N. Impact of Educational Mailing on the Blood Pressure of a Population of Primary Care Patients with Mild Hypertension. J Gen Intern Med. 2004 Sep;19(9):925- 30.

4. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther 2004; 26: 1518-1532.

5. Fuke D, Hunt J, Siemienczuk J, Estoup M, Touchette D. Low density lipoprotein goal attainment of patients with diabetes in a community-based primary care medical group. Am J Manag Care. 2004;10(part 2):130-136.

6. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with the use of thiazolidinediones: a Medicaid claims based case-control study. Pharmacotherapy 2005; 25(10): 1329-36.

7. Masica A, Touchette DR, Dolor R, Craft J, Kliethermes MA, Rodgers P, Lux L, Smith SR, Schumock GT. Evaluation of a medication therapy management program on patient safety in Medicare beneficiaries at high risk of adverse drug events: study methods. Advances in Patient Safety. Volume 4 / Technology and Medication Safety (AHRQ 08-0034-4) http://www.ahrq.gov/qual/advances2/#v1

8. Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, Touchette DR. Impact of pharmacy practitioners on management of hypertension: A randomized controlled trial. J Gen Intern Med 2008; 23(12):1966-1972.

9. Perez A, Doloresco F, Hoffman JM, Meek PD, Touchette DR, Vermeulen LC, Schumock GT. Economic Evaluations of Clinical Pharmacy Services 2001–2005. Pharmacotherapy 2009; 29(1): 128, with reference to Pharmacotherapy 2008; 28(11): 285e-323e.

10. Perez A, Touchette DR, DiDomenico RJ. Walton SM. Cost and effectiveness analysis comparing rate versus rhythm control for atrial fibrillation management with co-existing heart failure. Pharmacotherapy 2011; 31(6): 552-565.

11.Touchette DR, Rao S, Dhru P, Zhao W, Choi Y-K, Bhandari I, Stettin GD. Identification of and intervention to address therapeutic gaps in care in community pharmacies: The Illinois Project. Am J Manag Care 2012;18(10):e364-e371. 12. Touchette DR,Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, Smith SR. Safety-focused medication therapy

management: A randomized controlled trial. J Am Pharm Assoc 2012; 52: 603-612.

13. Gerber BS, Rapacki L, Castillo A, Tilton J, Touchette DR, Mihailescu D, Berbaum M, Sharp L. Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes. BMC Public Health 2012;12(1):891.

14. Kuo GM, Touchette DR, Marinac JS, for the American College of Clinical Pharmacy Practice-Based Research Network Collaborative. Drug errors and related interventions reported by United States clinical pharmacists: The American College of Clinical Pharmacy Practice-Based Research Network Medication Error Detection, Amelioration and Prevention study. Pharmacotherapy 2013; 33 (3): 253–265.

15. Lora CM, Sokolovsky AW, Touchette DR, Jin J, Hu X, Gao W, Gerber BS. ACE inhibitor and ARB medication use among Medicaid enrollees with diabetes. Ethnicity and Disease 2013; 23 (2): 189-195.

D. Research Support Ongoing Research Support

1R01DK091347 Sharp/Gerber (PI) 4/1/2011-3/31/2016

Health promoters and pharmacists in diabetes team management. Role: co-investigator

This grant provides funding for assessing the impact of health promoters in assisting study participants incorporate lifestyle changes necessary for improving the quality of life of persons with diabetes. Dr. Touchette will be leading the economic analysis and assessing participant adherence to medications.

Sunovion Pharmaceuticals Touchette (PI) 9/1/13-8/1/2016

Beliefs and attitudes towards antipsychotic use in patients with schizophrenia and bipolar disorder.

This contract is to develop and conduct a survey, within the American College of Clinical Pharmacy Practice-based Research Network, identifying clinical psychiatric pharmacist and physician beliefs and preferences for prescribing antipsychotic medications.

Pfizer Inc. Touchette (PI) 11/25/2013- 11/24/2015

ACIP pneumococcal immunization recommendations for adults with immunocompromising conditions – a scientific survey of

The purpose of this contract between Pfizer Inc. and the American College of Clinical Pharmacy Practice-based Research Network is to assess the operational, support, and attitudinal barriers to clinical practice guidelines for the prevention of pneumococcal disease in adults 19 years of age and older with immunocompromising conditions from the pharmacist’s perspective.

Completed Research Support

HHSA29020050038I TO2 Touchette (PI) 9/30/2005-5/30/2010

Design and Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries.

Agency for Healthcare Research and Quality.

This competitive grant is a DEcIDE Center Task Order to develop and evaluate a Medication Therapy Management (MTM) program. A prospective randomized trial of a comprehensive MTM program is being developed and conducted and its impact on patient health and safety evaluated..

HHSA29020050038I TO2 Touchette (PI) 9/1/2006-5/30/2010

Expansion of Design and Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries: A Multicenter, Randomized, Prospective, Study.

Agency for Healthcare Research and Quality.

This extension grant provides funding to expand the original competitve DEcIDE Center Task Order into a multicenter, randomized, prospective study. The Chicago area DEcIDE Center will serve as the coordinating site

for the study.

1U18HS016973-01 Lambert (PI) 7/1/2007-6/30/2011

Tools for Optimizing Prescribing, Monitoring and Education. Center for Education and Research on Therapeutics. Agency for Healthcare Research and Quality.

Role: Co-investigator.

This grant provides funding for a number of studies with a goal of improving the use of information in formulary decision making and prescribing. Dr. Touchette will be providing pharmacoeconomic support for several of the research projects.

UIC PAF 2010-00557 Touchette (PI) 3/10/2009- 6/30/2011

Assessment of Identification of Therapeutic Gaps and Community Pharmacist Intervention in State of Illinois Employees. Medco Health Solutions.

This contract provides funding to evaluate an intervention designed to reduce therapeutic gaps identified by Medco in State of Illinois employees. Identified therapeutic gaps are forwarded via a web-based platform to trained community pharmacists, most of who were from rural areas across Illinois.

W81XWH-09-1-0092 Touchette (PI) 11/26/2008-12/25/2012

Assessment of a Telepharmacy Robotic Medication Dispensing Unit in Miliary Warrior Transition Units. Department of Defense; INRange Systems Inc.

This grant provides funding for a clinical trial evaluating the effects of a robotic medication dispensing unit with its associated medication administration record on adherence, medication related problems, patient quality of life, and patient satisfation in soldiers with traumatic brain injury, post-traumatic stress disorder, or polytrauma. The study also assesses the costs, offsets, and cost-effectiveness of the unit.

Pharmacy Quality Alliance Crawford (PI) 4/1/2011-3/31/2013

PQA phase II demonstration project: Evaluation of modalities for delivering medication therapy management services. Role: co-investigator

This grant provides funding for a controlled comparison of telephonic and in-person medication therapy management on medication adherence and drug-related problems. Dr. Touchette will be providing support for various aspects of the study, including developing the pharmacist training and the development of methods and assessment of medication adherence and drug related problems.

11. Surrey Walton, PhD

NAME: Walton, Surrey M. POSITION TITLE: Associate Professor

eRA COMMONS USER NAME: SURREYW EDUCATION/TRAINING

INSTITUTION AND LOCATION DEGREE YEAR(s) FIELD OF STUDY

University of California Los Angeles, Los Angeles, CA

University of Chicago, Chicago, IL University of Chicago, Chicago, IL

BS MA PhD Economics Economics Economics A. Personal Statement

I would be pleased to serve as a faculty member and as a mentor for the proposed program. I currently coordinate and teach a required semester Pharm D level course titled “Principles of Pharmacoeconomics and Drug Treatment Outcomes, a required semester graduate course titled “Principles of the Economic Evaluation of Health Care Interventions,” and I have led several independent study courses related to economic

evaluation of health care services. I also have served as a mentor for numerous Master and PhD level graduate students, fellows, and PharmD students, including being the chair of ten graduate thesis committees. My areas of research and expertise are in quantitative economic evaluation of health services, health economics,

pharmacoeconomics, and evaluation of health care labor markets. I am confident that the proposed program will be highly successful and serve to effectively expand the availability of qualified CER and

PCOR researchers. B. Professional Positions

1995 Lecturer, University of Chicago, 1995.

1997-2004 Assistant Professor, Dept. of Pharmacy Admin., Univ. of Illinois at Chicago (UIC). 2004-2009 Director, Midwest Center for Health Workforce Studies, UIC.

1997-Present Adjunct Assistant Professor, Dept. of Economics, UIC.

2008-Present Assistant Director, Center for Pharmacoeconomic Research, UIC. 2004-Present Associate Professor, Department of Pharmacy Administration, UIC. C. Selected Peer Reviewed Publications

1. DiDomenico, RJ, Bauman, JL, Sanoski, CA, and Walton, SM, “Cost Benefit Analysis of the Use of Digoxin Immun Fab for the Treatment of Non-Life Threatening Digoxin Toxicity,” Journal of Cardiovascular Pharmacology and Therapeutics, 2000; 5 (2):77-85.

2. Walton, SM, Conrad, KM, Furner, SE and Samo, D, “Cause, Type, and Cost of Injury to Firefighters,” American Journal of Industrial Medicine, 2003; 43(4): 454-458.

3. Byczek, L., Walton, S.M., Conrad, K.M., Reichelt, P.A., & Samo, D.G. “Cardiovascular risks in firefighters: Implications for occupational health nurse practice,” AAOHN Journal, 2004; 52(2): 66-76.

4. Walton, SM, “The Pharmacist Shortage and Medication Errors: Issues and Evidence,” Journal of Medical Systems, 2004; 28(1): 63-69.

5. Schumock GT, Walton, SM, Park, HY, Nutescu, EA, Lewis, RK, Finley, JM, Blackburn JC, “Factors that Influence Prescribing Decisions,” Annals of Pharmacotherapy, 2004; April, Vol 38: 557-562.

6. Wang, Z, Salmon, JW, Walton, SM, “The Role of Cost Effectiveness Analysis in the Formulary Decision- making Process,” Journal of Managed Care Pharmacy, 2004;10(1): 48-59.

7. Schumock, GT, Blackburn, JC, Nutescu, EA, Walton, SM, Finley, JM, Lewis, R “Impact of Prescribing Guidelines for Inpatient Anticoagulation,” Annals of Pharmacotherapy, 2004; Vol. 38: 1570-1575.

8. Hatoum, HT, Keye, R, Marrs, RP, Walton, SM, Marshall, DC, “A Markov Model of the Cost Effectiveness of Human-Derived FSH Versus Follitropin. Infertility and Sterility, 2005; 83(3): 804-807.

9. Schumock, GT, Walton, SM, Guptz, SR, Cramer, JA “Cost analysis of divalproex ER compared to valproic acid in the treatment of bipolar disorder,” Current Medical Research and Opinion,2007;23(8):1997-2004.

10. Walton, SM, Schumock,GT, Lee, K, Alexander, GC, Meltzer, D, Stafford, RS. “Prioritizing FutureResearch on Off-Label Prescribing: Results of a Quantitative Evaluation,” Pharmacotherapy, 2008;28(12): 1443-1452. 11. Schumock, GT, Walton, SM, Lee, TA, Marx, SE, Audhya, P, Andress, DL, “Comparative Effectiveness of

Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,” Nephron Clinical Practice, 2011;117, c151-c159.

12. Walton, SM, Schumock, GT, McLain, DA, “Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA.” Current Medical Research and Opinion, 2010; 26(9), 2253-2261.

13. Liu, XL, Alexander, GC, Crawford, SY, Pickard, AS, Hedeker, H, Walton, SM, "Impact of Medicare Part D onOut of Pocket Costs for Prescriptions, Medication Utilization,Health Resource Utilization, and Preference- Based Health Utility," Health Services Research, 2011; 46(4),1104-1123.

14. Perez, A, Touchette, DR, DiDomenico, RJ, Stamos, TD, Walton, SM "Comparison of RateControl versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Cost Effectiveness Analysis," Pharmacotherapy, 2011; 31(6),552-565.

15. Falck, S, Adimadhyam, S, Meltzer, DO, Walton, SM, Galanter, WL, "A Trial of Indication Based Prescribing of Antihypertensive Medications During Computerized Order Entry to Improve Problem List Documentation," Int. J. Med Inform, 2013, http://dx.doi.org/10.1016/j.ijmedinf.2013.07.003IJB-3019

D. Research Support